571
Views
12
CrossRef citations to date
0
Altmetric
Review Articles

Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents

, , , , , , & show all
Pages 215-261 | Received 07 Jul 2018, Accepted 11 Feb 2019, Published online: 13 Jun 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Eleftherios Teperikidis, Aristi Boulmpou, Victoria Potoupni, Satyabrata Kundu, Balpreet Singh & Christodoulos Papadopoulos. (2023) Does the long-term administration of proton pump inhibitors increase the risk of adverse cardiovascular outcomes? A ChatGPT powered umbrella review. Acta Cardiologica 78:9, pages 980-988.
Read now
Inès Ben Ghezala, Maxime Luu & Marc Bardou. (2022) An update on drug–drug interactions associated with proton pump inhibitors. Expert Opinion on Drug Metabolism & Toxicology 18:5, pages 337-346.
Read now

Articles from other publishers (10)

Tingting Geng, Jun-Xiang Chen, Yan-Feng Zhou, Qi Lu, Zhenzhen Wan, Liegang Liu, An Pan & Gang Liu. (2023) Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism 108:6, pages e216-e222.
Crossref
Naina Mohamed Pakkir Maideen. (2023) Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Medical Journal 59:2, pages 115.
Crossref
Michael Nolde, Nayeon Ahn, Tobias Dreischulte, Evamaria Krause, Florian Güntner, Alexander Günter, Roman Gerlach, Martin Tauscher, Ute Amann, Jakob Linseisen, Christa Meisinger, Sebastian-Edgar Baumeister & Ina-Maria Rückert-Eheberg. (2022) Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: A systematic review and meta-analysis of observational studies. European Journal of Internal Medicine 106, pages 80-89.
Crossref
Ju-Young Park, Joonsang Yoo, Jimin Jeon, Jinkwon Kim & Sangwook Kang. (2022) Proton Pump Inhibitors and Risk of Cardiovascular Disease: A Self-Controlled Case Series Study. American Journal of Gastroenterology 117:7, pages 1063-1071.
Crossref
Philip O. Katz, Kerry B. Dunbar, Felice H. Schnoll-Sussman, Katarina B. Greer, Rena Yadlapati & Stuart Jon Spechler. (2022) ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology 117:1, pages 27-56.
Crossref
Michael Nolde, Nayeon Ahn, Tobias Dreischulte, Ina‐Maria Rückert‐Eheberg, Florian Güntner, Alexander Günter, Roman Gerlach, Martin Tauscher, Ute Amann, Jakob Linseisen, Christa Meisinger & Sebastian‐Edgar Baumeister. (2021) The long‐term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008‐2018). Alimentary Pharmacology & Therapeutics 54:8, pages 1033-1040.
Crossref
Elizabeth M. Salvo, Nicole C. Ferko, Sarah B. Cash, Ailish Gonzalez & Peter J. Kahrilas. (2021) Umbrella review of 42 systematic reviews with meta‐analyses: the safety of proton pump inhibitors. Alimentary Pharmacology & Therapeutics 54:2, pages 129-143.
Crossref
Ying Lian Xiao, Li Ya Zhou, Xiao Hua Hou, Yan Qing Li, Duo Wu Zou & Min Hu Chen. (2021) Chinese expert consensus on gastroesophageal reflux disease in 2020. Journal of Digestive Diseases 22:7, pages 376-389.
Crossref
Michael Nolde, Martin Bahls, Nele Friedrich, Marcus Dörr, Tobias Dreischulte, Stephan B. Felix, Ina‐Maria Rückert‐Eheberg, Nayeon Ahn, Ute Amann, Edzard Schwedhelm, Henry Völzke, Markus M. Lerch, Jakob Linseisen, Christa Meisinger & Sebastian E. Baumeister. (2021) Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: A cross‐sectional study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:2, pages 198-204.
Crossref
Nawal Farhat, Nicholas Birkett, Nisrine Haddad, Yannick Fortin, Franco Momoli, Shi Wu Wen, Andreas Wielgosz, Doug S. McNair, Donald R. Mattison & Daniel Krewski. (2020) Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel and Proton Pump Inhibitor Treatment: A Nested Case–Control Study. Drugs - Real World Outcomes 7:3, pages 191-203.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.